Corvus Pharma Com (CRVS)

$15.84 -0.13 (-0.81%)
Market Cap 1.33B
Revenue (ttm) 0.00
Net Income (ttm) -15.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,366,500
Avg Vol 1,270,182
Day's Range N/A - N/A
Shares Out 84.09M
Stochastic %K 64%
Beta 0.94
Analysts Strong Sell
Price Target $33.33

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hid...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 900 4520
Address:
901 Gateway Boulevard, Third Floor, South San Francisco, United States
Jellysquid1
Jellysquid1 May. 13 at 9:14 PM
$CRVS Attention! Shorts are Going To Try Hard To Scare you Into Selling Going into Conference Tomorrow Know What You Own!
1 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 8:48 PM
$CRVS 🚨VOTE NOW!
1 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 8:45 PM
$CRVS looks like the markets are expecting real limp data tomorrow
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 7:11 PM
$CRVS I’m expecting $14 easily by Monday
1 · Reply
tradingjunk321
tradingjunk321 May. 13 at 6:36 PM
$CRVS Personally I see Moore than that with our best 18.4 million friends!
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 6:31 PM
$CRVS could be a blood bath Friday. Be very very careful
1 · Reply
KingKai2020
KingKai2020 May. 13 at 6:06 PM
$CRVS loading up on Fri 18.000 calls for .20 Which i see as excellent risk/reward
0 · Reply
TheGunnerAB
TheGunnerAB May. 13 at 5:42 PM
$CRVS Shorts are playing with fire 🔥 as usual. SI in CRVS jumped to 18.4M shares, up from 7M shares a year ago.
1 · Reply
Jellysquid1
Jellysquid1 May. 13 at 2:24 PM
$CRVS MILLER TIME TOMORROW!
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 1:30 PM
$CRVS
1 · Reply
Latest News on CRVS
Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

2026-05-07T21:26:08.000Z - 6 days ago

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:01 PM EDT - 6 days ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Apr 23, 2026, 7:30 AM EDT - 20 days ago

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Apr 21, 2026, 7:30 AM EDT - 22 days ago

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

2026-04-17T08:45:23.000Z - 26 days ago

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

2026-03-13T12:16:32.000Z - 2 months ago

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Corvus Pharmaceuticals files automatic mixed securities shelf

2026-03-13T12:08:45.000Z - 2 months ago

Corvus Pharmaceuticals files automatic mixed securities shelf

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 2 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

2026-03-12T20:05:16.000Z - 2 months ago

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 12, 2026, 4:01 PM EDT - 2 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings

2026-03-12T19:45:16.000Z - 2 months ago

Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Mar 5, 2026, 4:01 PM EST - 2 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings

2026-03-04T20:45:14.000Z - 2 months ago

Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings

Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 2:40 PM EST - 2 months ago

Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 4:01 PM EST - 2 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

2026-01-29T11:51:48.000Z - 3 months ago

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Jan 23, 2026, 5:00 PM EST - 3 months ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies

2026-01-22T17:30:16.000Z - 3 months ago

Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies

Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15

2026-01-22T13:40:42.000Z - 3 months ago

Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 21, 2026, 10:53 PM EST - 3 months ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer

2026-01-21T13:50:38.000Z - 4 months ago

Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer

Corvus Pharmaceuticals announces $150M common stock offering

2026-01-20T21:10:39.000Z - 4 months ago

Corvus Pharmaceuticals announces $150M common stock offering

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 20, 2026, 4:01 PM EST - 4 months ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

2026-01-20T20:30:11.000Z - 4 months ago

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:10 PM EST - 4 months ago

What made Corvus stock double on Tuesday and is it sustainable?

Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho

2026-01-20T17:35:42.000Z - 4 months ago

Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho

Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright

2026-01-20T16:05:45.000Z - 4 months ago

Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright

Corvus Pharmaceuticals Transcript: Study result

Jan 20, 2026, 8:00 AM EST - 4 months ago

Corvus Pharmaceuticals Transcript: Study result

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 16, 2026, 4:01 PM EST - 4 months ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

Corvus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 6 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 6 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 31, 2025, 7:30 AM EDT - 6 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 28, 2025, 4:01 PM EDT - 7 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 17, 2025, 10:00 AM EDT - 7 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Oct 2, 2025, 4:01 PM EDT - 7 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 8, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 23, 2025, 4:08 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Apr 9, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Corvus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 27, 2025, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Corvus Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 9:20 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corvus Pharmaceuticals Transcript: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Study Update

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Corvus Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Corvus Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Corvus Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

May 30, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2024

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

May 2, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

May 2, 2024, 8:30 AM EDT - 2 years ago

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 9, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2023

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Jellysquid1
Jellysquid1 May. 13 at 9:14 PM
$CRVS Attention! Shorts are Going To Try Hard To Scare you Into Selling Going into Conference Tomorrow Know What You Own!
1 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 8:48 PM
$CRVS 🚨VOTE NOW!
1 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 8:45 PM
$CRVS looks like the markets are expecting real limp data tomorrow
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 7:11 PM
$CRVS I’m expecting $14 easily by Monday
1 · Reply
tradingjunk321
tradingjunk321 May. 13 at 6:36 PM
$CRVS Personally I see Moore than that with our best 18.4 million friends!
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 6:31 PM
$CRVS could be a blood bath Friday. Be very very careful
1 · Reply
KingKai2020
KingKai2020 May. 13 at 6:06 PM
$CRVS loading up on Fri 18.000 calls for .20 Which i see as excellent risk/reward
0 · Reply
TheGunnerAB
TheGunnerAB May. 13 at 5:42 PM
$CRVS Shorts are playing with fire 🔥 as usual. SI in CRVS jumped to 18.4M shares, up from 7M shares a year ago.
1 · Reply
Jellysquid1
Jellysquid1 May. 13 at 2:24 PM
$CRVS MILLER TIME TOMORROW!
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 13 at 1:30 PM
$CRVS
1 · Reply
Jellysquid1
Jellysquid1 May. 13 at 1:16 PM
$CRVS REMINDER… CRVS Will Be Presenting TOMORROW NEW DATA For SOQUELITINIB At The Sid Conference (Society For Investigative Dermatology)
1 · Reply
tradingjunk321
tradingjunk321 May. 13 at 11:35 AM
$CRVS Phelps feels the same about the short position going into tomorrow, 😂
2 · Reply
lousjamsession
lousjamsession May. 13 at 5:28 AM
$CRVS
0 · Reply
dwsrph1
dwsrph1 May. 12 at 6:56 PM
$CRVS I don’t think shorts are winning! Wait til Thursday Friday different story. Shorts are screwed!!
1 · Reply
Jellysquid1
Jellysquid1 May. 12 at 6:27 PM
$CRVS Squeeze Time Approaching!
1 · Reply
dwsrph1
dwsrph1 May. 12 at 6:11 PM
$CRVS I think we have a squeeze coming? What ya think?
1 · Reply
Jellysquid1
Jellysquid1 May. 12 at 5:42 PM
$CRVS Med Dic Losing so much money He is even trying his Hardest to land a job at Wendy’s! He should have bought CRVS!😁
2 · Reply
dwsrph1
dwsrph1 May. 12 at 4:56 PM
$CRVS hey Jelly! Do you think med Dic is a 🐓🍭!?? 😆😁😂
1 · Reply
dwsrph1
dwsrph1 May. 12 at 4:53 PM
$CRVS where’s that med Dic? Oh forgot I have him blocked because he is a 🐓🍭 😝😝
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 12 at 4:11 PM
$CRVS tears of the pumpers. I told people and they didn’t listen. Now they are feeling the pain
0 · Reply
dwsrph1
dwsrph1 May. 12 at 4:06 PM
$CRVS better start covering!!!!! 😁
1 · Reply
dwsrph1
dwsrph1 May. 12 at 4:05 PM
$CRVS if you’re short; bless you!!!!😂😂😂
1 · Reply